• Investors
  • News
  • Careers
  • Contact
Vaxart Home Button
  • Global Need
    • Vaccines
    • History & Impact
  • Our Solution
    • Oral Vaccines
    • Technology
    • Vaccine Advantages
    • Platform Advantages
  • Pipeline
    • Research & Development
    • Norovirus
    • Influenza
    • RSV
    • HPV
  • About Us
    • Our Mission
    • Our Team
    • Careers
    • Contact
    • Compliance
  • Investors
  • News
  • Careers
  • Contact

Single

1955

In the face of a devastating polio epidemic, Jonas Salk believed that a vaccine with a “killed” polio virus could safely immunize without the risk of infection. In 1955, it was announced that Salk’s poliovirus vaccine was 80-90% effective against paralytic polio. Upon adoption of the vaccine, the average number of polio cases in the U.S. dropped from more than 45,000 to just 910. It is unlikely, however, that Salk was surprised by this success. His confidence in the protective powers of his vaccine was so high that, two years earlier, he had administered the vaccine to himself, his wife and their three sons.

Reference: History of Salk: About Jonas Salk. Salk Institute. www.salk.edu/about/history-of-salk/jonas-salk. Accessed May 2016.

Post navigation

Previous PostPrevious
Next PostNext
Media Contacts

Katie Hogan, WCG
415.658.9745
khogan@wcgworld.com

Samir Singh, Vaxart
908.720.622,4
ssignh@vaxart.com

Get Updates

Subscribe to receive news alerts now.

© 2022 Vaxart, Inc., All rights reserved. Terms of UsePrivacy Policy